TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: rate of immune cells recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional capacity IADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional capacity ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional capacity TUG
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Diarrhea Using the Bowel Symptom Score (BSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants With an Undetectable HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adduction of foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural Avoidance Test (BAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac motion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distribution of HPV genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: fecal microbial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knowledge of TGNC Individuals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Knowledge of TGNC Cohort About Transgender Medical Issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Qualitative Shift in Confidence of TGNC Individuals in Seeking Medical Care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median time to complete cytogenetic response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Log in to SHUTi Per Week During the Last 9 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Time Spent on SHUTi After Logging in
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants Response to SHUTi Helpfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance of walking during 6-min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relation of resistance Rp : Rs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour ambulatory blood pressure mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Fuster-BEWAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to death, tracheostomy or permanent assisted ventilation
Endpoint domain: Mortality/survival
Primary endpoint: change in 2 hour post prandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: leukemia recurrence
Endpoint domain: Mortality/survival
Primary endpoint: GVHD, acute and chronic
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombin generation result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Taste and smell changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium release from bovine enamel and dentin specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Serum 25-(OH) D level at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Serum parathyroid hormone (PTH) levels at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline in Serum C-reactive Protein at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural Activation for Depression Scale (BADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Forced Expiratory Volume in One-second (FEV1) Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume change of fatty layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of post-operative levetiracetam monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incremental costs of COPD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number/variety of bacteria obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in semen quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Immune response measured by intracellular cytokine staining (ICCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of POCT PCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nervous assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Work ability index
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hypoglycaemic symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDSS Score Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial adhesion to tissue cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: microbial population shifts in vaginal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in average daily neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in blood serum inflammatory biomarker hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ARU on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-infection of the wound
Endpoint domain: Adverse events/effects
Primary endpoint: Skin suture incompetence
Endpoint domain: Adverse events/effects
Primary endpoint: Contraception efficacy
Endpoint domain: Physiological/clinical
Primary endpoint: Release of Premenstrual Dysphoric Disorder (PMDD) or acne
Endpoint domain: Physiological/clinical
Primary endpoint: Cmax for Norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for Norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf for Norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Corrected Total Estrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for Corrected Total Estrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf for Corrected Total Estrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response rate in EGFR exon 20 mutant NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate in HER2 exon 20 mutant NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Five-time Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological deficit evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uptake of disclosure invitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Single fiber specific force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of medication adherence for at least 1 year
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the tablet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with febrile infection
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Score Visual Analog Scale (VAS) 6 Hours Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Visual Analog Scale (VAS) 12 Hours Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Visual Analog Scale (VAS) 18 Hours Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Visual Analog Scale (VAS) 24 Hours Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: keloid and scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pigmentation disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in MADRS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Days of Inhaler Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved Symptoms score on KCCQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Ejection Fraction on ECHO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved distance during 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cycle Threshold (Ct) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PASI75 Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Injection-site complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Systematic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Blood, liver and kidney functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: abused drug abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICIQ-LUTSqol questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: uroflow/PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Horizontal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Steady-state Plasma Concentration-time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Modified Lee White Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Specificity of Modified Lee White Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in blood chemistry - BUN, Creatinine and Uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rebound at 120 minutes post-SL removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma/serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kappa coefficient for intra and inter-rater agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power of induced seizure on EEG recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful completion of study intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cellulite severity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-eradication time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Number of Incontinent Episodes During 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Professional Quality of Life Scale-IV (ProQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resilience Scale for Adults
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time Within Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of postnatal sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal or neonatal death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of benign or malignant recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Drug-Related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Correct Information Units (CIU)/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIUs/phrase elicited during spontaneous speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants who had Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who had Disease Related Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of day Hospital Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in SHIM Score (Score of Erectile Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Intra-operative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Resource Utilization in Dementia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of tissue expander(s) removed due to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of tissue expander(s) removed due to patient preference
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in UCLA GIT score for diarrhea or bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of unstable plaque occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistence with Avonex PEN therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in Forearm Blood Flow (FBF) After Tetraethylammonium (TEA) Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plantar pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient level of cooperation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence and nature of cytologic changes in ductal epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proportion of patients that are progression-free at 24 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in frequency of partial seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Inability to feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in any major or minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Multidimensional Assessment of Interoceptive Awareness (MAIA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with treatment-emergent adverse events related to the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Change in transcutaneous carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in patient-ventilator asynchronies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported continuous smoking cessation validated by exhaled carbon-monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EULAR clinical response (an improvement in DAS28 of >0.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recurrence or persistent disease
Endpoint domain: Mortality/survival
Primary endpoint: Pathological down-staging as measured by depth of extramural spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants With a 50% Reduction in Parathyroid Hormone (PTH) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite score of changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under curve (AUC) in classification performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient agreement with the IPRA© advices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative rate of MMR
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to Study Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Unprotected behavior at most recent vaginal or anal sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetrative sex at most recent hookup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes about sexual violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Distance Walked During the 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of high-risk sexual practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: progression of valvular changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete or almost complete resolution of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Texture and colour change of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of acute malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uterine contraction frequency during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Siltuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of ECMO on severe ARDS management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac fibrosis measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac fibrosis measured histologically
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dynamic uptake and washout of 123-I AV94
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in clinical laboratory test results for CBC with differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline for blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of asymptomatic teeth without clinical signs of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes